Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
26 hedge funds and large institutions have $29.1M invested in Bellerophon Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less capital invested
Capital invested by funds: $31.9M → $29.1M (-$2.77M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.13M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$227K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$195K |
| 4 |
TI
Telemetry Investments
New York
|
+$142K |
| 5 |
VMI
VHCP Management III
New York
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$24K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$18.4K |
| 3 |
VF
Virtu Financial
New York
|
-$14.9K |
| 4 |
BlackRock
New York
|
-$3.1K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$3K |
BLPH Hedge Fund Activity: Q1 2019 in Review
26 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q1 2019, worth a combined $29.1M — down 8.7% from $31.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BLPH positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.13M. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $24K sold.
- 26 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q1 2019, up from 25 in Q4 2018.
- Funds reported $29.1M of Bellerophon Therapeutics, Inc. stock for Q1 2019, down 8.7% quarter-over-quarter.
- 5 funds opened new Bellerophon Therapeutics, Inc. positions in Q1 2019 and 4 closed out, a net change of +1 holder.
- The largest Bellerophon Therapeutics, Inc. buyer in Q1 2019 was Armistice Capital, an estimated $2.13M added.
- The largest Bellerophon Therapeutics, Inc. seller in Q1 2019 was A.R.T. Advisors, an estimated $24K sold.
Based on aggregated 13F filings for Q1 2019.